- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
MiNK Therapeutics Accepted for ATS 2026 Conference
Biotech firm to present research on allogeneic natural killer cell therapies
Apr. 1, 2026 at 1:13pm
Got story updates? Submit your updates here. ›
MiNK Therapeutics, a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer cell therapies, has announced that an abstract submitted by the company has been accepted for presentation at the American Thoracic Society (ATS) 2026 International Conference.
Why it matters
Acceptance into the prestigious ATS conference is an important milestone for MiNK, as it validates the scientific merit of the company's research and provides a platform to share its findings with the broader medical community. Invariant natural killer cell therapies represent a novel approach to cancer treatment that could have significant implications for patients.
The details
The accepted abstract details MiNK's research on the use of allogeneic invariant natural killer cell therapies for the treatment of solid tumors. The company's proprietary technology aims to leverage the unique properties of these cells to mount a potent anti-tumor immune response.
- MiNK Therapeutics announced the abstract acceptance on April 1, 2026.
The players
MiNK Therapeutics, Inc.
A clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer cell therapies for the treatment of solid tumors.
What’s next
MiNK Therapeutics will present its research findings at the ATS 2026 International Conference, which is scheduled to take place in May 2026.
The takeaway
MiNK Therapeutics' acceptance into the prestigious ATS conference demonstrates the growing recognition and potential of its innovative approach to cancer treatment using allogeneic invariant natural killer cell therapies.
